Burchell, Sherrefa R. BS*; Dixon, Brandon J. BS*; Tang, Jiping MD*; Zhang, John H. MD, PhD*†
ISOFLURANE AND OTHER VOLATILE ANESTHETICS
Isoflurane is a volatile anesthetic that has been in clinical practice for several decades. Volatile anesthetics are also known as inhalational anesthetics and, apart from isoflurane, also include sevoflurane, desflurane, halothane, and enflurane. Of the 5 major volatile anesthetics, isoflurane, sevoflurane, and desflurane are most commonly used today. Halothane and enflurane are not used widely because of undesirable side effects.1 The volatile anesthetics all differ in potency, adverse effects, and cost and are used extensively during surgery in human neonates and during neonatal animal research. Moreover, volatile anesthetics are used in about 80% of the surgeries in the United States that are performed under general anesthesia.2 Volatile anesthetics have been reported to produce their effects by a number of mechanisms, including antagonism of ionic channels, activation of glycine and γ-aminobutyric acid (GABA) receptors and alteration of the function and activity of other cellular proteins, as well as through utilizing high lipid solubility characteristics.3,4
Isoflurane (2-chloro-2-[difluoromethoxy]-1,1,1-trifluoro-ethane, CHF2-O-CHCl-CF3), has been shown to be more potent than several other anesthetics. It is much more widely used in comparison to the other fluorinated inhalational anesthetics.5 Isoflurane was discovered in 1965 by Dr Ross Terrell and associates in their quest for a better inhaled anesthetic than was available at the time and was the 469th compound found, following enflurane and halothane.5 Isoflurane has a minimum alveolar concentration of 1.15% and blood/gas partition coefficient of 1.4, lower than that of most other inhaled anesthetics.6 Also, isoflurane is very stable and is resistant to biodegradation.3 These properties of isoflurane allow it to rapidly induce unconsciousness and also to be quickly eliminated from circulation.
ISOFLURANE IS PROTECTIVE IN VARIOUS ANIMAL MODELS
Isoflurane has been studied in animal models of various diseased states, such as lipopolysaccharide-induced acute inflammation of the lung,7 acute lung injury,8 glucose-induced oxidative stress,9 renal ischemia-reperfusion injury,10,11 cardiac injury,12 and so on. In these models, it is shown to provide protection from injury and improve various negative functional outcomes. The protective effects of isoflurane in these models are reported to occur through the activation of several pathways and are briefly outlined in Table 1.
In particular, isoflurane shows neuroprotection in several stroke models including subarachnoid hemorrhage (SAH),13 middle cerebral artery occlusion (MCAO),14,15 intracerebral hemorrhage,16 traumatic brain injury,17 and neonatal hypoxic ischemic (HI) brain injury18 (Table 1). For this review, the main focus will be on the neuroprotection of isoflurane as studied in neonatal HI, its possible mechanisms of action, and what direction this could be leading us in terms of clinical applications of isoflurane treatment.
Neonatal hypoxia ischemia is a major cause of mortality and neurological deficits such as cerebral palsy, mental retardation, and epilepsy in the perinatal period.19,20 Several factors have been implicated in the pathophysiology of HI, including inflammatory mediators, excitotoxicity, and oxidative stress.21 Although extensive research has been done on this form of brain injury, there is a gap between the basic and clinical sciences as successful treatments are still lacking. There are still a significant number of neonates who suffer from perinatal HI and its repercussions, approximately 1 in 4000, a figure 2 to 3 times higher than the incidence of childhood stroke.22 The methods of interventions are often limited for neonatal HI, because neuronal cell death is frequently only delayed, although it usually appears to be prevented shortly after an assault. Thus, it is essential that more preclinical studies be carried out to elucidate the possibility of an effective therapy that will provide long-term neuroprotection against HI in the perinatal period, reducing the effects seen up to adulthood.
To study neonatal HI brain injury, the Rice-Vannucci model is the one that is most widely used. Induction is most commonly with isoflurane at 3% and occurs for 4 minutes, followed by ligation of the right common carotid artery in rat pups. Isoflurane is continuously infused for the duration of the surgery (typically not >5 minutes) at 2.5%. The inspired concentration of isoflurane is lowered (from 3% to 2.5%) as this compensates for the decreased uptake due to the equilibration of isoflurane in the body following the induction period.5 The pups are then subjected to a hypoxic chamber with 8% oxygen at 37°C for 2.5 hours. Infarction volumes are calculated, and other neurological assessments are done at different time points after surgery. This method has been modified from that described by Rice et al.23 and is most commonly done in postnatal day 7 or 10 rats. Postnatal day 7 rat pups represent a human fetus at gestational age 32 to 34 weeks or a newborn infant at this stage,24 whereas postnatal day 10 rats are similar to the older neonate approaching adolescent stages of development or a full-term neonate.25
NEUROPROTECTION OF ISOFLURANE IN NEONATAL HI: POSSIBLE MECHANISMS
The use of isoflurane as an anesthetic in the surgery for modeling neonatal HI, along with the great variations observed in infarct sizes within and among litters, particularly as surgery times varied has led to speculations on the effects that isoflurane may be having on these neonates. This, among other reasons, has therefore sparked the interest in studying whether isoflurane may be providing some form of neuroprotection against ischemic injury in neonatal rat pups.
As a result, several studies have found that isoflurane, when it is administered before or after an experimental HI insult (preconditioning and postconditioning) in neonates, has the ability to reduce negative outcomes. Studies indicate that isoflurane acts through a number of mechanisms that are involved with neuroprotection and an increase in neuronal viability (Fig. 1). It has been suggested that isoflurane inhibits excitotoxicity that is initiated by an accumulation of glutamate during ischemia, resulting in a reduction in necrosis. The antagonism of glutamate receptors by isoflurane has been shown in in vitro studies, as well as in in vivo models, where isoflurane reduced extracellular glutamate during ischemia.26 In addition, isoflurane has been shown to be a GABA receptor agonist, providing an inhibitory effect against excitotoxicity.3
Under hypoxic conditions, isoflurane was shown to be protective via its interaction with the pathways that involve phospholipase C and the release of Ca2+ from intracellular stores. Phospholipase C triggers the phosphatidylinositol-3-kinase/protein kinase B and mitogen-activated protein kinase (PI3K/Akt/MAPK) pathways, which are antiapoptotic.27 Isoflurane also induced neuroprotection by altering the phosphorylation states of players in both the calcium-dependent and calcium-independent MAPK pathways, increasing the phosphorylation of some of the kinases (Pyk-2, extracellular signal–related kinase [ERK], MKK-6, JNK), while decreasing the phosphorylation of the downstream MAPK-dependent transcription factors (p38, pElk-1 p90 RSK, ATF-2). Phosphorylation of the MAPKs was prevented by an inositol triphosphate (IP3) receptor antagonist, suggesting that this phenomenon after isoflurane preconditioning depends on the small increases in intracellular Ca2+. The study also showed that isoflurane enabled neurons to avoid potentially toxic levels of Ca2+ increase. Moreover, there was an observed increase in the levels of Akt, an antiapoptotic protein, due to isoflurane preconditioning.27,28 The activation of the Akt pathway was also observed in a model of oxidative and inflammatory stress on cardiac myocytes. Isoflurane was shown to prevent apoptosis by activating Akt and enhancing B-cell lymphoma 2 (Bcl-2) expression.29,30
Furthermore, isoflurane was shown to protect against oxygen glucose deprivation-induced ischemia in neuronal cultures by activating the cell-surviving protein, hypoxia-inducible factor 1α, and the subsequent increase in expression of inducible nitric oxide synthase (iNOS) mRNA. Notably, the protection observed with isoflurane preconditioning was also dependent on the ERK pathway; an ERK1/2 inhibitor partially reversed the protective effects that resulted from isoflurane administration.31 The aforementioned studies were mainly carried out in in vitro models of hypoxia, and although they may provide clearer mechanistic pathway descriptions, they differ from the physiology seen in intact animals. However, similar neuroprotection has been observed in vivo.
In a study done in an animal model of neonatal HI, Chen et al.25 hypothesized that longer isoflurane exposure times may be one of the underlying factors leading to the inconsistent results in infarction volumes observed in the model. The results showed that longer surgery times, and hence longer isoflurane exposure, resulted in decreased infarction severity in the rat pups. Pups that had exposure times to isoflurane of 13 or 21 minutes had significantly less volume of infarction than those with only 5 minutes of exposure: 33.2% in the 5-minute group versus 20.3% in the 13-minute group and 11.3% in the 21-minute group in the 7-day old pups. This trend was also observed in the10-day-old rat pups (24.8% in the 5-minute group vs 11.9% in the 13-minute group and 9.3% in the 21-minute group).25
By extension, this group also did experiments to elucidate the mechanism by which isoflurane was participating in this neuroprotective role. They found that the sphingosine-1-kinase/PI3K/Akt (S1P/PI3K/Akt) pathway is active in this function as administration of selective inhibitors of S1P (VPC23019) and PI3K (wortmannin) completely reversed the effects of isoflurane-induced neuroprotection. Importantly, isoflurane provided both short- and long-term neuroprotection as effects were observed up to 4 weeks after the HI injury, when neurobehavioral tests were carried out. The effect of the S1P and PI3K inhibitors had a long-term effect as well, reversing the improvement in neurobehavior induced by longer exposures to isoflurane. Also, Akt phosphorylation was preserved in the isoflurane pretreated group, and a significant reduction in cleaved caspase 3 levels was observed. These findings confirmed the speculation of the involvement of the S1P/PI3K/Akt pathway.18 In addition, in an SAH model, isoflurane was also shown to be neuroprotective by activating the sphingosine kinase/S1P (SK/S1P) pathway. Isoflurane treatment attenuated the disruption of the blood-brain barrier that usually occurs after SAH.13
The involvement of the S1P/PI3K/Akt pathway in protection has also been implicated by other groups in different models of ischemia. Isoflurane was found to protect against renal dysfunction, significantly lowering plasma creatinine values and tubular necrosis, an effect abrogated by SK and S1P receptor antagonists, providing further evidence that their activity is essential to isoflurane-induced protection against ischemia. In addition, mice lacking the SK1 enzyme were not protected against injury from ischemia.10 The S1P pathway involvement in protection was seen in cardiac ischemia-reperfusion injury also as the administration of S1P, which activated the S1P receptor, resulted in reduced infarct sizes, leukocyte recruitment, and adhesion.32 In models of liver ischemia, the SK/SIP pathway was also shown to be activated. There was a significant improvement in hepatic function in both normal and cirrhotic livers, increased anti-inflammatory cytokine production, and down-regulation of antiapoptotic genes following ischemia-reperfusion injury due to the activation of S1P.33
Volatile anesthetics, including isoflurane, have been proposed to exhibit potency as a result of their high lipid solubility.3 This theory was proposed by Meyer and Overton in 1901 and has been used to explain the involvement of the lysophospholipid, sphingosine-1-phosphate, which results from the activation of sphingomyelin hydrolysis.34 Sphingomyelin is a lipid component of the membrane, which is hydrolyzed to ceramide, a precursor of sphingosine. Sphingosine is then converted to S1P by the enzyme SK.10 Spingosine kinase is involved in many different biological processes including cell growth and cell survival.35 In addition, SK and S1P have been shown to up-regulate the ERK/MAPK pathway, resulting in increased cell survival.36,37 A significant finding was that animals with a knockout of the SK gene could not be protected by isoflurane treatment.10,38 These studies all correlate with the Lipid Theory, which describes the potency of volatile anesthetics in relation to lipid solubility. However, in recent years, the Protein Theory, which postulates that anesthetics act directly on proteins rather than accumulating in membranes, has stimulated a lot of interest.3,39
Consequently, other mechanisms have been proposed on how isoflurane confers neuroprotection. One such pathway is through the activation of iNOSs. Zhao and Zuo22 found that isoflurane induced an increase in nitric oxide and suggested that this may be the mediator for the neuroprotection induced by isoflurane. They confirmed this by the use of a nitric oxide inhibitor, aminoguanidine, which abolished the neuroprotection conferred by isoflurane.22 Isoflurane neuroprotection was shown using a preconditioning model, where isoflurane was given at 1.5% for 30 minutes 24 hours before the hypoxic insult. Neuroprotection was measured up to 7 days after injury.
In another study by the same group, it was found that the brain loss induced by HI was significantly attenuated up to 1 month after injury, when animals were preconditioned with 1.5% isoflurane for 30 minutes 24 hours before injury. This conclusion was made as there were no significant differences between control and isoflurane-treated groups in long-term reference memory, as well as short-term working memory. Isoflurane also significantly improved motor coordination 1 month after injury. In addition, preconditioning with isoflurane resulted in increased Bcl-2 expression in the hippocampus40; Bcl-2 can decrease the release of cytochrome C and mitochondrial membrane permeability caused by ischemic episodes.40 Again, it was found that the protection by isoflurane could be reversed by administration of an iNOS inhibitor, suggesting a role for iNOS in the isoflurane-induced neuroprotection. Small increases in iNOS protein expression have been associated with cardioprotection and neuroprotection. Inducible nitric oxide synthase is believed to be an important factor for protection because protein kinase C and MAPK are both located downstream of iNOS and are believed to provide protection.41 Notably, isoflurane was found to increase the p38 MAPK phosphorylation status after an ischemic injury, and the protection induced by preconditioning with isoflurane was abolished by the administration of a p38 MAPK inhibitor.42
Kapinya et al.43 also found that isoflurane preconditioning resulted in an increase in iNOS in an MCAO model and suggested that the increase in iNOS may be the means by which isoflurane reduces infarction volume and other neurological deficits. However, they also stated that further study is needed to identify the underlying anesthetic mechanism as the increase in iNOS was not observed until 6 hours after the preconditioning event, whereas protection was seen immediately after preconditioning with isoflurane.43 Nitric oxide is known to interact with 2 survival pathways: the Ras/Raf/MEK/ERK pathway and the PI3K/Akt pathway.44 Both of these pathways are essential to neuronal survival and could therefore be the underlying mechanism by which the isoflurane-induced increase in iNOS is protective in brain injury models. However, there is some contradiction in this area as nitric oxide has been shown to be both protective and toxic.44 Therefore, there are still further studies that need to be done to clarify the neuroprotection of isoflurane via an increase in iNOS.
The studies described above show a long-term neuroprotective role of the anesthetic, isoflurane. This is significant as a large percentage of infants who have neonatal HI do survive into adulthood; however, most of them have residual motor and cognitive deficits.21 However, importantly, there have been contradictions on whether the neuroprotection provided by isoflurane is long term or only transient. A study done by McAuliffe et al.45 suggested that isoflurane may be useful in preventing the deficits seen long after the neonatal injury or at least reducing the severity. This conclusion was made from experiments that showed that preconditioning with isoflurane improved striatal function in adulthood. Neurobehavioral testing was also done by the use of a water maze with adult mice that had undergone neonatal HI and was done at 70 days old. Mice preconditioned with isoflurane performed as well as sham in this neurobehavioral test, and this therefore provides evidence for long-term neuroprotection.45
By contrast, Sasaoka et al.20 found that preconditioning with isoflurane at 2% for either 60 or 90 minutes before the HI insult induced ischemic tolerance in the hippocampus of postnatal day 7 rat pups up to 7 days after the injury, but not at 49 days. These results suggest that the neuroprotective effect of isoflurane is only transient. This may be due to the rapid removal of isoflurane from the system as a result of small amounts of biodegradation, as stated before.
It has also been suggested that isoflurane preconditioning may simply be delaying neuronal injury, not preventing it. This idea was proposed based on results that showed that brain infarction in the isoflurane-treated group was significantly reduced in comparison to controls 2 days following ischemic injury, but this reduction was not seen 14 days after the insult. However, isoflurane did reduce the number of necrotic cells in the penumbral area 2 weeks after ischemia was induced.46 This experiment was carried out in an adult model of ischemia. Nevertheless, it still presents a significant consideration to be made with regard to the use of isoflurane for neuroprotection clinically because the delay in neuronal injury provided by isoflurane may provide a longer therapeutic window for other interventions.
It is clear that isoflurane exhibits neuroprotective properties, and harnessing this capability of the volatile anesthetic may be very relevant clinically. However, although isoflurane has been shown to be beneficial in numerous cases, before it can be used as a neuroprotective therapy for neonatal HI, several concerns have to be addressed. One such consideration is the length of time that isoflurane is administered. Studies have shown that isoflurane exposure for periods of 3 to 6 hours resulted in caspase activation and neuronal death,47,48 in contrast to the potent neuroprotection observed with shorter exposure times.25,40 Therefore, studies specifically aimed at establishing an optimal time period within which there is still effective neuroprotection from isoflurane, without causing neurotoxicity, have to be done.
There are contradictory evidences in support of isoflurane playing a neuroprotective role, while at the same time potentially being neurotoxic. As discussed above, there are many animal studies that show isoflurane to be convincingly neuroprotective. However, evidence based on clinical studies in humans is not as strong.4 And although there is not much evidence on the neurotoxicity resulting from isoflurane anesthesia, the fact that there is any is reason for considerations to be made in this regard before clinical isoflurane therapy can progress substantially.
Isoflurane studies are clinically relevant and translatable because the percentage of isoflurane used experimentally is around 1.15% to 2%, which is comparable to a minimum alveolar concentration of 1.15% in human adults and 1.6% in human neonates.40 However, different researchers have found the most effective dosages to be different in their models. With these discrepancies, much more would need to be done to establish what the optimal dosage of isoflurane is that will be most effective, providing maximal neuroprotection to infants.
Another factor that is very important to consider is elucidating the exact mechanism by which isoflurane provides protection from cell death and other negative outcomes. Several different pathways have been implicated to date. The first postulate on the mechanism of action of isoflurane and other volatile anesthetics was that they exhibited more potency the more soluble they were in lipids.3 Because the membrane is composed mainly of lipids, they were thought to act through membrane lipids. Hence, sphingosine and SK were suggested to be involved. From this theory, several studies carried out in various models have shown that isoflurane provides neuroprotection by activating this pathway, which then up-regulates the ERK/MAPK/Akt pathway, resulting in increased cell growth and survival. However, newer theories indicate a more protein-based mechanism of action, via several ion channels, as well as GABA and glutamate receptors. The involvement of iNOS in isoflurane-mediated neuroprotection is another popular mechanism proposed and is more in line with the Protein Theory. Notably, many of these pathways, including sphingosine-1-phosphate and iNOS, exhibit protection via the activation of the ERK/MAPK/Akt pathway. This is significant and may be the way to connect the different pathways implicated, thereby establishing how isoflurane is protecting neurons from cell death.
Finally, neonatal HI results from several different pathophysiological manifestations. Hence, it may be necessary to target more than one of these to provide sufficient neuroprotection. Consequently, using isoflurane along with another intervention may be much more effective. Moreover, with the suggestion by some studies that isoflurane is merely delaying repercussions from ischemia, rather than preventing them, this may open a longer therapeutic window for other interventions to be applied and may also provide an additive protective effect.
The possibility of using isoflurane clinically is very promising, and with the fact that it is already so widely used, addressing the current concerns would prove very beneficial in progressing not only the field of neonatal brain injury, but also many diseases related to hypoxia and ischemia.
1. Matchett GA, Allard MW, Martin RD, et al. Neuroprotective effect of volatile anesthetic agents: molecular mechanisms. Neurol Res. 2009; 31:(2): 128–134.
2. Loepke AW, McCann JC, Kurth CD, et al. The physiologic effects of isoflurane anesthesia in neonatal mice. Anesth Analg. 2006; 102:(1): 75–80.
3. Antkowiak B. How do general anaesthetics work? Naturwissenschaften. 2001; 88:(5): 201–213.
4. Zuo Z. Are volatile anesthetics neuroprotective or neurotoxic? Med Gas Res. 2012; 2:(1): 10
5. Eger EI 2nd. Isoflurane: a review. Anesthesiology. 1981; 55:(5): 559–576.
6. Eger EI 2nd. The pharmacology of isoflurane. Br J Anaesth. 1984; 56:(suppl 1): 71S–99S.
7. Chung IS, Kim JA, Kim JA, et al. Reactive oxygen species by isoflurane mediates inhibition of nuclear factor kappaB activation in lipopolysaccharide-induced acute inflammation of the lung. Anesth Analg. 2013; 116:(2): 327–335.
8. Harr JN, Moore EE, Stringham J, et al. Isoflurane prevents acute lung injury through ADP-mediated platelet inhibition. Surgery. 2012; 152:(2): 270–276.
9. Kinoshita H, Matsuda N, Iranami H, et al. Isoflurane pretreatment preserves adenosine triphosphate-sensitive K(+) channel function in the human artery exposed to oxidative stress caused by high glucose levels. Anesth Analg. 2012; 115:(1): 54–61.
10. Kim M, Kim M, Kim N, et al. Isoflurane mediates protection from renal ischemia-reperfusion injury via sphingosine kinase and sphingosine-1-phosphate–dependent pathways. Am J Physiol Renal Physiol. 2007; 293:(6): F1827–F1835.
11. Lee HT, Ota-Setlik A, Fu Y, et al. Differential protective effects of volatile anesthetics against renal ischemia-reperfusion injury in vivo. Anesthesiology. 2004; 101:(6): 1313–1324.
12. Lang XE, Wang X, Zhang KR, et al. Isoflurane preconditioning confers cardioprotection by activation of ALDH2. PLoS One. 2013; 8:(2): e52469
13. Altay O, Suzuki H, Hasegawa Y, et al. Isoflurane attenuates blood-brain barrier disruption in ipsilateral hemisphere after subarachnoid hemorrhage in mice. Stroke. 2012; 43:(9): 2513–2516.
14. Li H, Yin J, Li L, et al. Isoflurane postconditioning reduces ischemia-induced nuclear factor-kappaB activation and interleukin 1beta production to provide neuroprotection in rats and mice. Neurobiol Dis. 2013; 54: 216–224.
15. Li L, Zuo Z. Isoflurane postconditioning induces neuroprotection via Akt activation and attenuation of increased mitochondrial membrane permeability. Neuroscience. 2011; 199: 44–50.
16. Khatibi NH, Ma Q, Rolland W, et al. Isoflurane posttreatment reduces brain injury after an intracerebral hemorrhagic stroke in mice. Anesth Analg. 2011; 113:(2): 343–348.
17. Statler KD, Alexander H, Vagni V, et al. Isoflurane exerts neuroprotective actions at or near the time of severe traumatic brain injury. Brain Res. 2006; 1076:(1): 216–224.
18. Zhou Y, Lekic T, Fathali N, et al. Isoflurane posttreatment reduces neonatal hypoxic-ischemic brain injury in rats by the sphingosine-1-phosphate/phosphatidylinositol-3-kinase/Akt pathway. Stroke. 2010; 41:(7): 1521–1527.
19. Vannucci SJ, Hagberg H. Hypoxia-ischemia in the immature brain. J Exp Biol. 2004; 207:(pt 18): 3149–3154.
20. Sasaoka N, Kawaguchi M, Kawaraguchi Y, et al. Isoflurane exerts a short-term but not a long-term preconditioning effect in neonatal rats exposed to a hypoxic-ischaemic neuronal injury. Acta Anaesthesiol Scand. 2009; 53:(1): 46–54.
21. Ferriero DM. Neonatal brain injury. N Engl J Med. 2004; 351:(19): 1985–1995.
22. Zhao P, Zuo ZY. Isoflurane preconditioning induces neuroprotection that is inducible nitric oxide synthase–dependent in neonatal rats. Anesthesiology. 2004; 101:(3): 695–702.
23. Rice JE 3rd, Vannucci RC, Brierley JB. The influence of immaturity on hypoxic-ischemic brain damage in the rat. Ann Neurol. 1981; 9:(2): 131–141.
24. Vannucci RC, Connor JR, Mauger DT, et al. Rat model of perinatal hypoxic-ischemic brain damage. J Neurosci Res. 1999; 55:(2): 158–163.
25. Chen H, Burris M, Fajilan A, et al. Prolonged exposure to isoflurane ameliorates infarction severity in the rat pup model of neonatal hypoxia-ischemia. Transl Stroke Res. 2011; 2:(3): 382–390.
26. Warner DS. Isoflurane neuroprotection: a passing fantasy, again? Anesthesiology. 2000; 92:(5): 1223–1225.
27. Bickler PE, Fahlman CS. The inhaled anesthetic, isoflurane, enhances Ca2+-dependent survival signaling in cortical neurons and modulates MAP kinases, apoptosis proteins and transcription factors during hypoxia. Anesth Analg. 2006; 103:(2): 419–429,
table of contents
28. Gray JJ, Bickler PE, Fahlman CS, et al. Isoflurane neuroprotection in hypoxic hippocampal slice cultures involves increases in intracellular Ca2+ and mitogen-activated protein kinases. Anesthesiology. 2005; 102:(3): 606–615.
29. Jamnicki-Abegg M, Weihrauch D, Pagel PS, et al. Isoflurane inhibits cardiac myocyte apoptosis during oxidative and inflammatory stress by activating Akt and enhancing Bcl-2 expression. Anesthesiology. 2005; 103:(5): 1006–1014.
30. Gwak MS, Cao L, Li L, et al. Isoflurane preconditioning reduces oxygen-glucose deprivation-induced neuronal injury via B-cell lymphoma 2 protein. Environ Toxicol Pharmacol. 2011; 31:(1): 262–265.
31. Li QF, Zhu YS, Jiang H. Isoflurane preconditioning activates HIF-1alpha, iNOS and Erk1/2 and protects against oxygen-glucose deprivation neuronal injury. Brain Res. 2008; 1245: 26–35.
32. Theilmeier G, Schmidt C, Herrmann J, et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation. 2006; 114:(13): 1403–1409.
33. Man K, Ng KT, Lee TK, et al. FTY720 attenuates hepatic ischemia-reperfusion injury in normal and cirrhotic livers. Am J Transplant. 2005; 5:(1): 40–49.
34. Lochhead KM, Zager RA. Fluorinated anesthetic exposure “activates” the renal cortical sphingomyelinase cascade. Kidney Int. 1998; 54:(2): 373–381.
35. Pyne S, Pyne N. Sphingosine 1-phosphate signalling and termination at lipid phosphate receptors. Biochim Biophys Acta. 2002; 1582:(1–3): 121–131.
36. Bakar AM, Park SW, Kim M, et al. Isoflurane protects against human endothelial cell apoptosis by inducing sphingosine kinase-1 via ERK MAPK. Int J Mol Sci. 2012; 13:(1): 977–993.
37. Pitson SM, Moretti PA, Zebol JR, et al. Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J. 2003; 22:(20): 5491–5500.
38. Kim M, Park SW, Kim M, et al. Isoflurane activates intestinal sphingosine kinase to protect against renal ischemia-reperfusion–induced liver and intestine injury. Anesthesiology. 2011; 114:(2): 363–373.
39. Franks NP, Lieb WR. Where do general anaesthetics act? Nature. 1978; 274:(5669): 339–342.
40. Zhao P, Peng L, Li L, et al. Isoflurane preconditioning improves long-term neurologic outcome after hypoxic-ischemic brain injury in neonatal rats. Anesthesiology. 2007; 107:(6): 963–970.
41. Zuo Z, Wang Y, Huang Y. Isoflurane preconditioning protects human neuroblastoma SH-SY5Y cells against in vitro simulated ischemia-reperfusion through the activation of extracellular signal–regulated kinases pathway. Eur J Pharmacol. 2006; 542:(1–3): 84–91.
42. Zheng S, Zuo Z. Isoflurane preconditioning induces neuroprotection against ischemia via activation of P38 mitogen-activated protein kinases. Mol Pharmacol. 2004; 65:(5): 1172–1180.
43. Kapinya KJ, Lowl D, Futterer C, et al. Tolerance against ischemic neuronal injury can be induced by volatile anesthetics and is inducible NO synthase dependent. Stroke. 2002; 33:(7): 1889–1898.
44. Huang PL. Nitric oxide and cerebral ischemic preconditioning. Cell Calcium. 2004; 36:(3–4): 323–329.
45. McAuliffe JJ, Joseph B, Vorhees CV. Isoflurane-delayed preconditioning reduces immediate mortality and improves striatal function in adult mice after neonatal hypoxia-ischemia. Anesth Analg. 2007; 104:(5): 1066–1077,
tables of contents
46. Kawaguchi M, Kimbro JR, Drummond JC, et al. Isoflurane delays but does not prevent cerebral infarction in rats subjected to focal ischemia. Anesthesiology. 2000; 92:(5): 1226–1228.
47. McAuliffe JJ, Loepke AW, Miles L, et al. Desflurane, isoflurane, and sevoflurane provide limited neuroprotection against neonatal hypoxia-ischemia in a delayed preconditioning paradigm. Anesthesiology. 2009; 111:(3): 533–546.
48. Jevtovic-Todorovic V, Hartman RE, Izumi Y, et al. Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits. J Neurosci. 2003; 23:(3): 876–882.